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Abstract 
Objective: 
This article reviews rational approaches to treating attention-deficit/hyperactivity disorder 
(ADHD) in preschool children, including pharmacological and nonpharmacological treatments. 
Implications for clinical practice are discussed. 
Data Sources: 
We searched MEDLINE, PsychINFO, Cumulative Index to Nursing & Allied Health, Educational 
Resources Information Center, Cochrane Database of Systematic Reviews and Database of Abstracts of 
Reviews of Effects for relevant literature published in English from 1967 to 2007 on preschool ADHD. We 
also reviewed the references cited in identified reports. 
Study Selection: 
Studies were reviewed if the sample included at least some children younger than 6 years of age or 
attending kindergarten, the study participants had a diagnosis of ADHD or equivalent symptoms, received 
intervention aimed at ADHD symptoms, and included a relevant outcome measure. 
Data Extraction: 
Studies were reviewed for type of intervention and outcome relevant to ADHD and were rated for 
the level of evidence for adequacy of the data to inform clinical practice. 
Conclusions: 
The current level of evidence for adequacy of empirical data to inform clinical practice for short-
term treatment of ADHD in preschool children is Level A for methylphenidate and Level B for parent 
behavior training, child training, and additive-free elimination diet. 
Introduction 
Attention deficit/hyperactivity disorder (ADHD) frequently begins between 2 and 4 
years of age (Connor 2002; Egger and Angold 2006). It is associated with significant impairment 
in terms of emotional distress for the preschool child and the caregivers (DuPaul et al. 2001), 
expulsion from daycare or early education settings (Blackman 1999), demands on the caregiver’s 
time, exclusion from family events, and accident proneness and other safety concerns (Lahey et 
al. 2004; Rappley et al. 1999). Children with ADHD have comorbid mental health and chronic 
health problems and are frequent users of the healthcare system (Rappley et al. 2002). As shown 
by several prospective longitudinal follow up studies, behavior problems in preschool children 
persist to school-age years and continue to be associated with significant impairment (Campbell 
and Ewing 1990; Campbell et al. 2000; Egeland et al. 1990; Fischer et al. 1984; Lahey et al. 
2004; Lavigne et al. 1998; McGee et al. 1991; Richman et al. 1982). In a recent study, 79.2% of 
the preschool children who met full diagnostic criteria for ADHD and 34.5% of the preschool 
children who met criteria in one situation only at initial assessment continued to meet full ADHD 
diagnostic criteria and exhibited global academic and social impairment three years later (Lahey 
et al. 2004). 
Impairment from ADHD and persistence of problems at later ages underscores the need 
for early intervention in preschool children with ADHD (Beckwith 2000; Bierman et al. 2007; 
Campbell 2002; Conduct Problems Prevention Research Group 1999; Elliot et al. 2002; Petras et 
al. 2008; Shure et al. 2001). Recently, the Preschool Psychopharmacology Working Group 
(PPWG) reviewed pharmacological treatment studies in preschool children and proposed 
treatment algorithms for preschool psychiatric disorders (Gleason et al. 2007), however the 
nonpharmacological treatments for ADHD were not reviewed in detail. The primary objective of 
this paper is to review rational approaches to pharmacological and nonpharmacological treatment 
of ADHD in preschoolers and the implications for clinical practice. For the purposes of this 
paper, we define preschool age as prior to starting formal schooling, i.e., first grade. Hence, we 
reviewed studies that included children in kindergarten and/or younger than 6 years of age. The 
Food and Drug Administration (FDA) provides additional demarcation for children younger than 
6 years. Most of the pharmacological agents for treatment of ADHD are approved by the FDA 
only for children older than 6 years (with the exception of amphetamines), and the FDA 
considers their use in children younger than 6 years as “off-label.” 
Methods and Review 
We searched MEDLINE, PsychINFO, Cumulative Index to Nursing & Allied Health, 
Educational Resources Information Center, Cochrane Database of Systematic Reviews and 
Database of Abstracts of Reviews of Effects for relevant literature on treatment of preschool 
ADHD. We also reviewed the references cited in identified reports to locate other relevant 
studies. Due to limited literature in this area, we reviewed both controlled and non-controlled 
studies. The reviewed studies met the following inclusion criteria: Published in English in the 
past 40 years (between 1967 to 2007); included at least some children younger than 6 years of 
age and/or attending kindergarten who had a diagnosis of ADHD; or exhibited behavior 
problems that are part of the ADHD diagnostic criteria, involved intervention aimed at ADHD 
symptoms, and included an outcome measure to monitor ADHD symptoms. To determine the 
level of evidence to inform clinical practice, we adapted the International Psychopharmacology 
Algorithm Project criteria (Jobson and Potter 1995) previously used by Judice and Mayes (2003) 
to categorize psychopharmacology treatments in preschool children. Since most of the reviewed 
child training studies were single case design experiments (state of current evidence for child 
training studies), based on the Task Force on Promotion and Dissemination of Psychological 
Procedures guidelines (Task Force on Psychological Intervention Guidelines 1995) previously 
used by Chorpita et al. (2002) to assess efficacy of psychosocial treatment studies in children and 
adolescents, we modified the criteria to include single case design experiments in addition to 
randomized controlled trials. 
A treatment was considered to have evidence at Level A, if it demonstrated a significant 
difference on an ADHD outcome variable in a sample of preschoolers with a Diagnostic and 
Statistical Manual (DSM) diagnosis of ADHD in at least two randomized controlled trials (RCT) 
or two series of single case design experiments comparing randomly assigned active treatment to 
a comparison treatment or placebo. A treatment was considered to have evidence at Level B, if it 
demonstrated a significant difference on an ADHD outcome variable in a sample of preschoolers 
with a DSM diagnosis of ADHD in one RCT, two or more RCTs with mixed results, or one 
series of single case design experiments comparing randomly assigned active treatment to a 
comparison treatment or placebo. Level C was assigned to a treatment to indicate that data were 
based on uncontrolled trials, case reports, retrospective chart reviews, or informed clinical 
opinion. 
Treatment of Preschool Attention-Deficit/Hyperactivity Disorder 
Here we review the current available evidence for psychopharmacological and 
nonpsychopharmacological interventions (psychosocial and alternative treatments) and clinical 
implications for preschool children with ADHD. Prior to starting any treatment, it is important to 
conduct a comprehensive assessment that is contextually relevant and takes into account the 
rapid developmental changes occurring during preschool years. Because a comprehensive 
discussion of the assessment process for diagnosing ADHD in preschool children is beyond the 
scope of this paper, the reader is referred to several excellent reviews addressing preschool 
nosology, diagnosis, and assessment (Angold et al. 2004; Campbell 2002; Carter et al. 2004; 
Egger and Angold 2006; Emde et al. 1993; Task Force on Research Diagnostic Criteria: Infancy 
and Preschool 2003). In general, a multi-method and multi-informant evaluation extending over 
multiple appointments to assess symptomatology and impairment in multiple environments and 
caregiving contexts is recommended (Carter et al. 2004; Gleason et al. 2007). A combination of 
diagnostic interviews and parent and teacher rating scales, with psychometric data in 
preschoolers, are commonly employed to aid in the diagnostic and assessment process. Examples 
of the parent and teacher rating scales include Conners’ Rating Scales-Revised (CRS-R) 
(Conners 2001), Swanson, Nolan and Pelham (SNAP) rating scale (Swanson 1992), Child 
Behavior Checklist-1½(CBCL-1½) (Achenbach and Rescorla 2000), and ADHD Rating Scale 
(ADHD-RS) (DuPaul 1998; Gimpel and Kuhn 2000). The Preschool Age Psychiatric 
Assessment (PAPA) (Egger et al. 2006) is a reliable and valid semi-structured diagnostic parent-
interview that is widely used in research studies of preschool pathology. However, clinical 
settings may find the cost and length of the PAPA training and administration to be a barrier for 
its use in routine clinical practice. Nonetheless, adequate history, mental status examination, and 
collateral information are important for developing an appropriate treatment plan that addresses 
the biopsychosocial issues specific to each family. 
Psychopharmacological treatment 
There are several challenges to psychopharmacological treatment of preschool children 
with ADHD. Preschool age is a period of continued rapid neuronal maturation including synaptic 
remodeling and construction. Cortical synaptic density reaches its maximum at age 3 and is 
substantially modified by the pruning process from ages 3 to 7 years (Huttenlocher 1990). 
Cerebral metabolic rate peaks between 3 and 4 years of age (Chugani 1987). Aminergic systems 
play an important role in neurogenesis, neuronal migration, axonal outgrowth, and 
synaptogenesis (Coyle 1997) and are also the targets of action for many psychopharmacological 
agents as indicated by studies in preclinical models. Thus, clinicians are faced with a dilemma. 
On one hand, whether it is prudent to recommend exposing the rapidly developing brain of a 
preschool child to psychopharmacological agents. On the other hand, clinicians also need to 
consider the consequences of an untreated disorder. Early exposure to adverse environmental 
circumstances and stress has been shown to result in long-lasting impact on the brain and 
emotional regulation of animals and humans (Graham et al. 1999; Matthews 2002; Nemeroff 
2004). 
Information about the use of psychopharmacological agents for treatment of ADHD is 
available mostly for school age children. In school age children, psychostimulants are the 
mainstay of treatment for ADHD; nonstimulant psychopharmacological agents are frequently 
recommended as a second-line treatment if a school age child’s ADHD symptoms do not 
adequately respond to stimulants (Dulcan and Benson 1997). Recently, a nonstimulant 
psychopharmacological agent, atomoxetine, has been shown to be a safe and effective treatment 
of ADHD in school age children (Kratochvil et al. 2004; Michelson et al. 2001). Comparatively, 
there is limited information on the use of psychopharmacological agents for treatment of ADHD 
in preschool children. No pharmacokinetic and dose finding studies to identify dosage and 
frequency of drug administration in preschool children are available. Until recently, clinicians 
were left to extrapolate findings from older children to preschool children. However, medications 
used in older children may have specific toxicities in preschool children (Wigal et al. 2006), and 
there may be differences in efficacy in preschool children compared to school age children 
(Greenhill et al. 2006). Additionally, extrapolation to preschool children of data collected in 
older children is not always possible due to differences in development. 
There are over 250 published studies of psychopharmacological agents in school age 
children with ADHD (Wilens et al. 2002). In contrast, there are a total of 24 published reports 
(blinded and open-label studies) on the use of psychopharmacological agents involving over 495 
preschool children with ADHD. Of the 24 published reports (Tables 1 and 2), 20 published 
reports are on the use of stimulants, 2 published case reports on the use of α2 agonists, 1 
published case report on the use of atomoxetine, and 1 published case report on the use of 
fluoxetine in preschool children with ADHD. 
Psychostimulant studies. 
Of the 20 published studies on the use of stimulants in preschool children, 12 double-
blind group treatment studies (one parallel groups, 10 crossover and 1 ABA design) included 417 
preschool children treated with methylphenidate (MPH). Two double-blind MPH/ placebo 
crossover studies included both preschool and older children, but did not specify the number of 
preschool participants (Barkley 1988; Fischer and Newby 1991); and one blinded time series 
treated one preschool child with dextroamphetamine (Speltz et al. 1988). The remaining five 
published reports are open-label studies or case reports involving a total of 61 preschool children 
treated with MPH or dextroamphetamine (Alessandri and Schramm 1991; Byrne et al. 1998; 
Cohen et al. 1981; Ghuman et al. 2001; Stiefel and Dossetor 1998). 
Twelve of the fifteen blinded MPH studies treated typically developing preschool 
children with ADHD; seven studies included only preschool children (Barkley 1988; Conners 
1975; Firestone et al. 1998; Greenhill et al. 2006; Musten et al. 1997; Schleifer et al. 1975; Short 
et al. 2004; Speltz et al. 1988), while the other six studies included both preschool and older 
children (Barkley et al. 1988; 1985; 1984; Chacko et al. 2005; Cunningham et al. 1985; Fischer 
and Newby 1991). Of the other two studies, one included a mixture of inpatient or outpatient 
preschool and school age children with ADHD who were either typically developing or had 
autism or other developmental disorders (Mayes et al. 1994), and the one remaining blinded 
study treated preschool children with developmental disorders (Handen et al. 1999). The 
diagnostic procedure used most frequently included a combination of clinical interview and 
dimensional rating scales. With the exception of the recent PATS study, sample size was small 
ranging from 11–59, duration of the psychostimulant trials ranged from 3–9 weeks, and 
stimulant dose ranged from 0.15–0.6 mg/kg. Mixed outcomes were reported for efficacy. Based 
on direct observation of the preschool children’s nursery school behavior, one study reported no 
improvement with MPH compared to placebo (Schleifer et al. 1975). Positive response to MPH 
was reported by other investigators in 80%–83% of typically developing preschool children 
(Conners 1975; Greenhill et al. 2006; Short et al. 2004) and 71%–73% of preschool children 
with developmental disorders (Handen et al. 1999). Data on side effect profile in preschool 
children was also divergent. Rates of side effects ranged from minimal or clinically negligible 
(Conners 1975) to 89% in typically developing preschool children (Schleifer et al. 1975) and 
45%–50% in preschool children with developmental disorders (Handen et al. 1999; Mayes et al. 
1994). Dysphoria, crying, whining, irritability, and solitary play were more frequently reported 
in preschool children than seen in older children. 
The 6-site PATS study randomized 165 preschool children (3–5.5 years) diagnosed with 
ADHD in a placebo-controlled, double-blind crossover design, to one week each of 4 MPH 
doses (1.25 mg, 2.5 mg, 5 mg and 7.5 mg TID) and placebo. With the exception of the lowest 
MPH dose, improvements in parent- and teacher-rated ADHD symptoms were reported with 
MPH compared to placebo; the 7.5 mg TID dose was found to be the most effective. The effect 
sizes (Cohen’s d) in the intent-to-treat sample ranged from 0.4–0.8 and were smaller than those 
reported for school age children treated with MPH (Greenhill et al. 2006). Interestingly, 
secondary analyses of the PATS efficacy data showed that preschoolers with ADHD with no or 
one comorbid disorder (primarily oppositional defiant disorder [ODD]) had treatment responses 
(Cohen’s d = 0.89 and 1.00, respectively) at the same level as found in school age children 
(Ghuman et al. 2007). Preschoolers with 2 comorbid disorders had moderate treatment response 
(Cohen’s d = 0.56) and preschoolers with 3 or more comorbid disorders did not respond to MPH 
(Ghuman et al. 2007). However, caution is needed in the generalization of the findings as there 
were only 15 preschoolers (9% of the sample) with 3 or more comorbid disorders compared to 
150 preschoolers with two comorbid disorders (n = 34, 21% of the sample), one comorbid 
disorder (n = 69, 42% of the sample) or no comorbid disorders (n = 47, 28% of the sample). In 
addition to decreased appetite, stomach ache, and sleep difficulties usually seen in school age 
children, increased rates of social withdrawal and lethargy were reported especially at higher 
doses. A higher discontinuation rate (8.3%) due to MPH side effects was reported in the PATS 
study than the 0.5% discontinuation rate in the National Institute of Mental Health (NIMH) 
Multimodal Treatment of ADHD (MTA) study with school-age ADHD children (Wigal et al. 
2006). Compared with the Center for Disease Control (CDC) norms, the preschool children with 
ADHD in the PATS were 2.0 cm taller and 1.8 kg heavier at baseline. A 20% less than expected 
annual height gain (-1.38 cm/year) and 55% less than expected annual weight gain (-1.32 
kg/year) was reported for the children who continued MPH for a year in the open-label follow up 
phase (Swanson et al. 2006). Decrease in weight velocity was evident at the end of the 5-week 
double-blind crossover phase. Most preschoolers with ADHD were able to maintain 
improvement over 10 months of open-label follow up treatment (Vitiello et al. 2007).

 

 

Two of the open-label stimulant studies were prospective open-label treatment trials, two 
were case reports, and one was a retrospective chart review. Positive response to stimulants 
(MPH or dextroamphetamine) was reported in four of the open-label studies; one prospective 
treatment trial reported no treatment effect and reported a 30% discontinuation rate due to MPH 
adverse effects (Cohen et al. 1981). 
Non-stimulant studies. 
The two published case reports of open-label treatment with α2 agonists in 5 preschool 
children with ADHD reported improvement in hyperactive and impulsive behavior (Cesena et al. 
1995; Lee 1997), one published case report of open-label treatment with atomoxetine in 10 
preschool children reported improvement in hyperactive, impulsive and inattentive symptoms 
(Kratochvil et al. 2007), and one published case report of open-label treatment with fluoxetine in 
one preschool child with ADHD reported improvement in attention span (Campbell et al. 1995) 
(Table 3). 
Prescribing patterns. 
Despite controversy and scarcity of empirical information regarding dose guidelines, 
safety, and efficacy, psychopharmacological agents are being prescribed to preschool children. 
This is a serious public health concern and was identified as a research priority by the 
Surgeon General (National Institutes of Health 2000; US Public Health Service 2000) and the 
White House (Pear 2000). 
In 1994, 226,000 MPH prescriptions were written for children under 6 years of age (US 
Food and Drug Administration 1997). A three-fold increase in MPH use in 2–4 year old children 
was reported from 1991–1995 (Zito et al. 2000); Marshall (2000) reported that 150,000 to 
200,000 children between the ages of 2 and 4 years were estimated to be taking MPH. Outpatient 
prescription data from 7 state Medicaid programs revealed 67.3% stimulant and 26% α-agonist 
use in 2001 in 2–4 year old children treated with psychotropic agents (Zito et al. 2007). 
Pre-school children with ADHD symptoms are more often treated with stimulants in the 
community than with any other drug. Those not treated with stimulants, are often given other 
psychotropic medications, including those that have not been shown to have any efficacy in 
ADHD, such as selective serotonin reuptake inhibitors (SSRIs) (Rappley et al. 2002) and those 
with some efficacy for ADHD but leading to severe long-term adverse events (e.g., tardive 
dyskinesia), such as neuroleptics (Minde 1998; Rappley et al. 2002). Health Maintenance 
Organization (HMO) and Medicaid database surveys in 1995 showed frequent use of 
psychotropic medications in preschool children diagnosed with ADHD. Frequency of 
psychotropic drug prescription in 1–3 year old children diagnosed with ADHD (N = 223) in the 
Michigan Medicaid system was 57% (n = 127) compared to 26% (n = 47) for psychosocial 
intervention (Rappley et al. 1999). Psychotropic medications alone as a sole intervention strategy 
were utilized in 40% children (n = 89); comparatively psychosocial intervention as a sole 
treatment was utilized in only 9% (n = 21). Stimulants were prescribed for 93.7%, α2 agonists 
for 44.9%, tricyclic antidepressants for 33.1%, neuroleptics for 15.7%, and SSRIs for 11% of the 
preschool children receiving psychotropic medications. More than half of the children received 
treatment for longer than 6 months. Medication monitoring was inadequate—for 75 children 
(59%) follow-up visits occurred every 3 months and for 25 children (19%) at intervals greater 
than 6 months (Rappley et al. 2002). 
Summary of psychopharmacological treatments. 
There is evidence for short-term efficacy and long-term effectiveness and tolerability of 
psychostimulants, especially MPH, in preschool children with ADHD. Response is reported to 
be less robust and response rate is reported to be lower in preschool children with ADHD 
compared to older children. Preschool children with ADHD are sensitive to developing more 
side effects especially at higher doses and have unique adverse effect profile including more 
irritability and mood changes. This sensitivity to stimulant adverse effects may be a limiting 
factor in achieving an adequate and/or robust response in preschool children with ADHD. Only 
open-label information is available regarding effectiveness and tolerability of one non-stimulant, 
atomoxetine, in preschool children with ADHD. Additionally, pharmacological interventions 
may be effective in reducing core ADHD symptoms such as impulsivity, overactivity, and 
inattention among preschool children with ADHD (Greenhill et al. 2006); however, there is little 
evidence to suggest that psychostimulants improve long-term interpersonal relationships known 
to be important in predicting outcomes for children displaying disruptive behaviors (Coie and 
Dodge 1998; Pelham et al. 1998; Rubin et al. 2006). Moreover, no information is available about 
long-term safety and effects of psychopharmacological agents on brain development in preschool 
children. 
Psychosocial treatments 
Concerns about the short- and long-term safety of psychopharmacological agents 
especially on the developing brain of preschool children, coupled with ethical, societal, and 
political beliefs about manipulating behavior through medication and perceived overprescription 
(Jensen et al. 1999) often lead families and providers to favor other interventions for 
preschoolers (Dulcan and Benson 1997). In this section, we will review current evidence for 
success of psychosocial treatments in preschool children with ADHD. 

There is evidence from studies in school-age children that long-term behavioral 
improvements may require psychosocial interventions (Ialongo et al. 1993). Inhibitory processes 
play a critical role in impaired functioning in children with ADHD (Barkley 1997; Barkley 1998; 
Barkley 2003; Nigg 2001; Nigg 2003; Quay 1997) and these, although rudimentary, are 
developing rapidly during the preschool period (Davidson et al. 2006; Diamond and Taylor 
1996; Espy et al. 1999; Garon et al. 2008; Jones et al. 2003; Rueda et al. 2005). Psychosocial 
interventions targeting key executive functions, especially inhibitory processes, may be 
particularly helpful (Diamond et al. 2007; Dowsett and Livesey 2000). 
Limited psychosocial intervention research has been conducted with preschool samples 
of children formally diagnosed with ADHD (Bryant et al. 1999; McGoey et al. 2002); however, 
there is considerable evidence that parent, child, and parent-child interventions can reduce 
problem behaviors in young children displaying a range of disruptive behaviors, including 
excessive hyperactivity and inattention as reviewed in the following section. We have grouped 
the psychosocial intervention studies into those that train parents in behavioral techniques and 
use the parents as the primary agent of change, and those that train children in a classroom 
setting to reduce problematic behaviors. 
Parent training. 
Among psychosocial interventions, parent training to help parents learn and implement 
behavioral treatment has the strongest evidence base showing positive effects for school age 
children with ADHD (Chorpita and Daleiden 2002). For preschool children with ADHD, parent 
training in behavior management is an especially helpful and the most appropriate psychosocial 
intervention (Stanley and Stanley 2005; Webster-Stratton et al. 2001). When children are young, 
parents have an enormous impact on their child’s behavior (Capage et al. 1998; Eyberg et al. 
1995; Funderburk et al. 1998; Hembree-Kigin and McNeil 1995) creating a window of 
opportunity to teach parents how to be positive and consistent in their parenting responses, help 
reduce noncompliant and aggressive behaviors, and help their child persist at a difficult task and 
provide successful experiences for their child, thus reducing risk for continued problems in later 
years. Parent behavior training programs for preschool children have been modeled after 
efficacious programs developed with older children (Anastopoulos et al. 1993; Dishion and 
McMahon 1998), and draw upon both social-learning and attachment theories to varying extent. 
Parent training programs may include sessions with parents, parent-child dyad, or a combination 
of parent sessions and work with the parent-child dyad to improve parent-child relationship, and 
increase the child’s prosocial behaviors and decrease negative behaviors. 
There are 15 published reports of parent behavior training treatment trials (either 
controlled, case series or case reports) that monitored outcomes in ADHD symptoms in 
preschool children with a DSM diagnosis of ADHD or preschool children displaying ADHD 
symptoms (Tables 4 and 5). However, there was a wide variation in the study design, type of 
control groups, inclusion criteria, diagnostic measures, type of psychosocial intervention, method 
of intervention delivery, and outcome measures employed in the studies. Nine studies used a 
randomized parallel groups design with control groups ranging from wait-list, community 
treatment, combination treatment to minimal treatment (Barkley et al. 2000; Bor et al. 2002; 
Corrin 2004; Jones et al. 2007; McGoey et al. 2005; Pisterman et al. 1992; 1989; Sonuga- Barke 
et al. 2001; Strayhorn and Weidman 1989; Strayhorn and Weidman 1991) and six studies did not 
employ any control group (Chang et al. 2004; Danforth 1999; Drash et al. 1976; Erhardt and 
Baker 1990; Henry 1987; Huang et al. 2003). Eight of the nine controlled studies included only 
preschool children and four of these eight studies selected the preschoolers based on a DSM 
diagnosis of ADHD through clinical or structured parent interview (Bor et al. 2002; Pisterman et 
al. 1992; 1989; Sonuga-Barke et al. 2001), and the other four selected preschoolers based on a 
rating scale cutoff. The ninth controlled study included both preschool-age and school-age 
children with a DSM diagnosis of ADHD. Sample sizes ranged from 20-50 per group. Most 
studies employed group-training sessions except for three studies that employed individual 
training sessions with the parents (Bor et al. 2002; Henry 1987; Sonuga-Barke et al. 2001). 
Training was conducted over 8–12 sessions, each parent training session lasting 1–3 hours. Most 
studies included both teaching/ modeling sessions with the parents and work with the parent-
child dyad with the exception of one study that included parent training sessions only (Jones et 
al. 2007), one study that included parent and/or child training sessions separately (Corrin 2004) 
and two studies that included only didactic teaching sessions with the parents (Barkley et al. 
2000; Huang et al. 2003). Outcome assessments varied among the studies and included parent 
ratings of ADHD and disruptive behaviors, and direct behavior observation by independent 
raters for on-task behavior, child compliance with maternal commands, and parent-child 
interaction quality during structured play. 
Improvements in ADHD symptoms were reported in three of the eight controlled studies 
that included only preschool children (Jones et al. 2007; Sonuga-Barke et al. 2001; Strayhorn and 
Weidman 1989) and only one of these studies (Sonuga-Barke et al. 2001) was in preschoolers 
formally diagnosed with ADHD. Preschoolers diagnosed with ADHD (N = 78) were randomized 
to 8 weeks of parent training, parent counseling and support, or a wait-list group (Sonuga-Barke 
et al. 2001). Improvements in ADHD symptoms were reported with parent training compared to 
the other two conditions; positive effects were maintained at 6 month follow-up. No 
improvement in hyperactive, impulsive and/or inattentive symptoms on parent ratings or direct 
observation was reported in the remaining 5 controlled studies that included only preschool 
children. Improvements in ADHD symptoms were also reported in most of the non-randomized 
non-controlled case series (Drash et al. 1976; Erhardt and Baker 1990; Huang et al. 2003). 
With the exception of Barkley et al (2000), most investigators reported improvements in 
parenting skills, parenting style of interaction, and child compliance. Barkley et al. (2000) 
reported poor treatment response with parent behavior training in kindergarteners (N = 158) who 
met dimensional rating scale cutoff criteria for hyperactive, impulsive, inattentive, and 
aggressive behavior. The kindergarteners were assigned to one of four treatment groups: parent 
training only, classroom day treatment only, a combined condition, or a no treatment control 
group. The parent training intervention produced no effects. 
There may be several reasons for the poor treatment response in this study. Inclusion 
criteria for the study were based on a rating scale cutoff and no clinical or structured diagnostic 
interviews were conducted for a diagnosis of ADHD. Most important, neither the children’s 
caregivers nor their teachers had indicated impaired functioning in the kindergartners included in 
the study. There is evidence that psychosocial treatment approaches have greater impact on those 
children rated with higher levels of problems (Kellam et al. 1998; Wilson and Lipsey 2007). 
Furthermore, only 25% of the parents attended more than four parent behavior training sessions, 
and, finally, the parent behavior training was delivered in a didactic format.






